Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
PUMA Welcomes AC Milan Star Theo Hernández to the Family 
Skepta and PUMA Launch Groundbreaking Collection 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
How supermarkets are changing their branding to make you think they’re cheaper 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Cancer drug pollution is a growing global concern 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Coca-Cola Launches Data-Driven Insights Platform for Retail and Foodservice Industries 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
PRINCETON, N.J., March 04, 2016 -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, announced today that Gregory Mayes, Executive Vice President and Chief Operating Officer, will present a corporate overview at the 27th annual ROTH Capital Partners Conference in Dana Point, California.
The presentation, featuring 2016 company initiatives and key milestones, such as a soon to be launched Phase 3 trial for axalimogene filolisbac, is scheduled to take place on March 15, 2016 at 11:00 a.m. PST.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.
For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.
Forward-Looking Statements
This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
CONTACTS:
Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
[email protected]
609.250.7515
Media Contact:
JPA Health Communications
Catherine Brady
[email protected]
617.945.9316
